About Shattuck Labs
Shattuck Labs is a company based in Austin (United States) founded in 2016. Shattuck Labs has raised $165.4 million across 7 funding rounds from investors including Fidelity Investments, Orbimed and Janus Henderson Investors. The company has 44 employees. Shattuck Labs offers products and services including SL-325. Shattuck Labs operates in a competitive market with competitors including ALX Oncology, TScan Therapeutics, Lyell Immunopharma, Alpine Immune Sciences and Alector, among others.
- Headquarter Austin, United States
- Employees 44
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website shattucklabs.com
- Social LinkedIn X
- Legal Name Shattuck Labs, Inc.
- Annual Revenue$1 M (USD)-82.52as on Dec 31, 2025
- Net Profit-$48.81 M (USD)35.28as on Dec 31, 2025
- EBITDA-$47.84 M (USD)37.47as on Dec 31, 2025
- Total Equity Funding$165.4M (USD)
in 7 rounds
- Latest Funding Round$103M (USD), Post-IPO
Aug 2025
- InvestorsFidelity Investments
& 9 more
- Employee Count44
Products & Services of Shattuck Labs
Shattuck Labs offers a comprehensive portfolio of products and services, including SL-325.
Antagonist for Death Receptor 3 to block TL1A pathway in autoimmune diseases.
Funding Insights of Shattuck Labs
Shattuck Labs has successfully raised a total of $165.4M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $103 million completed in August 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $165.4M
- Total Rounds 7
- Last Round Post-IPO — $103M
- First Round $3.4M
(Aug 2016)
- Investors Count 10
All 7 funding rounds of Shattuck Labs with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2025 | $103M | Post-IPO | – | Orbimed | – |
| Jun 2020 | $83M | Series C | – | Redmile Group | |
| Feb 2020 | $25.38M | Series B | – | – | – |
| May 2018 | $46.62M | Series B | – | – | – |
| Apr 2017 | $7M | Series A | – | – | – |
| Mar 2017 | – | Seed | – | Hunter Trust | – |
| Aug 2016 | $3.4M | Seed | – | – | – |
10 investors in total: 10 institutional.
Investors in Shattuck Labs
Shattuck Labs has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Orbimed and Janus Henderson Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Tech & Life Sciences focused VC firm investing in early stage companies in the US & Europe | – | hatterasvp.com | Durham, United States | |
Healthcare companies are invested in by this private equity firm. | – | pfmhealthsciences.com | San Francisco, United States | |
A family investment office based in Minneapolis, USA, is operated. | – | huntertrust.com | Minneapolis, USA | |
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Operates as an employee-owned hedge fund focused on long/short equity strategies. | 2007 | redmilegroup.com | San Francisco, United States | |
Provider of brokerage accounts, retirement planning, wealth management, and trading platforms | 1946 | fidelity.com | Boston, United States | |
- | – | ecor1cap.com | - | |
- | – | emersoncollective.com | - | |
Advisory services for corporate mergers and acquisitions are provided. | 1895 | pipersandler.com | Minneapolis, United States |
Investor details for Shattuck Labs
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Shattuck Labs
36 people are tracked at Shattuck Labs (17 in leadership, 9 in board & advisors, 10 in team); the tracked headcount is 44.
| Name | Role | Group |
|---|---|---|
Simon Metenou | VP, Translational Medicine | Leadership |
Lini Pandite | Chief Medical Officer | Leadership |
Amy Franke | VP, Clinical Operations | Leadership |
Anne Lai | Director, Research And Development | Leadership |
Casi Deyoung | Chief Business Officer | Leadership |
Mahmud Hussain | Associate Director, R&d | Leadership |
Stephen Stout | General Counsel, Corporate Secretary, Chief Ethics & Compliance Officer | Leadership |
Abhinav A. Shukla | Chief Technical Officer | Leadership |
Andrew R. Neill | CFO | Leadership |
Taylor H. Schreiber | CEO & Co-Founder | Leadership |
George Fromm | Chief Scientific Officer, ARC Platform | Leadership |
Suresh De Silva | Chief Scientific Officer, GADLEN Platform | Leadership |
Amy Gibbs Franke | Vice President, Clinical Operations | Leadership |
Vishruti Makani | Director, Cell Sciences | Leadership |
Philip Jackson | Executive Director, Finance | Leadership |
Robert M Hernandez | Sr. Director Of Clinical Research | Leadership |
Bo Ma | VP, Biometrics | Leadership |
Helen M. Boudreau | Director | Board & advisors |
Kurt Schalper | Advisor | Board & advisors |
Michael Lee | Director | Board & advisors |
16 more people are available in the full profile.
Complete people profiles for Shattuck Labs
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Shattuck Labs
Shattuck Labs is a publicly listed company on the NASDAQ with ticker symbol STTK in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date09 Oct 2020
- Listed onNASDAQ: STTK
- Listed entityShattuck Labs, Inc.
- Exchange sectorHealth technology
- ISINUS82024L1035
- Share price$5.66 (+0.09% on the day) · 2026-10-08
- Market capitalisation$568.1M
- EPS (diluted, trailing year)$-0.51
- Volume (last session)2,486,606
Financials of Shattuck Labs
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $1.0M | -$48.8M | -$47.8M |
| 2024 | $5.7M | -$75.4M | -$76.5M |
| 2023 | $1.7M | -$87.3M | -$87.9M |
| 2022 | $652,000 | -$101.9M | -$100.0M |
| 2021 | $30.0M | -$45.0M | -$43.9M |
Detailed financial statements for Shattuck Labs
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Shattuck Labs
4 dated milestones of Shattuck Labs across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Shattuck Labs is founded.
- Funding First funding round of $3.4M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $103.0M.
Competitors of Shattuck Labs
Shattuck Labs operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ALX Oncology, TScan Therapeutics, Lyell Immunopharma, Alpine Immune Sciences and Alector, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| alxoncology.com | 2015 | Burlingame, United States | $123.02M | 59 | ALX Oncology is focused on advancing cancer treatment therapies. | |
| tscan.com | 1995 | Boston, United States | $158.3M | 154 | T cell-based treatments for immunological and oncological disorders are developed. | |
| lyell.com | 2018 | San Francisco, United States | $493M | 224 | CAR-T and TIL immunotherapies for solid tumors are developed. | |
| alpineimmunesciences.com | 2015 | Seattle, United States | $49.25M | 126 | Developer of immunotherapies to treat cancer and autoimmune disorders | |
| alector.com | 2013 | San Francisco, United States | $214.78M | 211 | Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | |
| hummingbirdbioscience.com | 2015 | Singapore | $150M | – | Antibody drugs for cancer treatment are developed. | |
| gigagen.com | 2011 | San Francisco, United States | $36.13M | 36 | T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | |
| oncoresponse.com | 2015 | Seattle, United States | $149.62M | 35 | Immunotherapies for cancer treatment are developed via proprietary antibody platform. |
Detailed competitors of Shattuck Labs
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Shattuck Labs
The website of Shattuck Labs (shattucklabs.com) receives about 3.8K visits a month and ranks #4,826,872 among all websites worldwide, #5,671 in Biotechnology and Pharmaceuticals.
- Monthly visits3.8K
▲ 7.1% vs previous month
- Unique visitors1.6K
per month
- Global rank#4,826,872
among all websites
- Category rank#5,671
Health · Biotechnology and Pharmaceuticals
- Bounce rate40%
- Pages per visit1.7
- Average visit1 min 30 sec
- DevicesDesktop 52% · Mobile 48%
Latest news on Shattuck Labs
Complete news archive for Shattuck Labs
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Shattuck Labs
10 companies that operate in the same segment as Shattuck Labs (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Shattuck Labs
Shattuck Labs was founded in 2016.
Shattuck Labs is headquartered in Austin, United States. It is registered at Austin, Texas, United States.
Shattuck Labs is a funded company, having raised a total of $165.4M across 7 funding rounds to date. The company's 1st funding round was a Seed of $3.4M, raised on Aug 2016.
Shattuck Labs has 44 employees.
Annual revenue of Shattuck Labs is $1M as on Dec 31, 2025.
Shattuck Labs was founded in 2016 and is headquartered in Austin, United States. The company operates in the biotechnology sector, focusing on oncology and immunology. Its core platform, known as ARC (Agonist Redirected Checkpoints), involves bispecific biologics designed to block checkpoint molecules in cancer while stimulating TNF superfamily costimulatory receptors on T cells and innate immune cells. This approach is applied to various checkpoint targets under clinical development.
Shattuck Labs's top competitors include Alector, Hummingbird Bioscience and Lyell Immunopharma.
Shattuck Labs offers SL-325.
Yes, Shattuck Labs is publicly traded on NASDAQ under the ticker symbol STTK.
Shattuck Labs has 10 investors. Key investors include Fidelity Investments, Orbimed, Janus Henderson Investors, Piper Sandler, and Redmile Group.
Shattuck Labs operates through Shattuck Labs, Inc..